Our Approach Portfolio ICYMI
Member Login

The Venture Collective.

Empowering Founders Who Are Transforming Legacy Industries

Who We Are.

TVC is a transformational, early-stage venture firm backed by world class entrepreneurs and business leaders. We invest our capital, time, and network into highly defensible, fast-growing companies with the potential to solve the world's biggest problems.

The $11 Trillion Opportunity .

“The Great Wealth Transfer” is starting to occur with the oldest baby boomers currently in their 70s, which will generate a new approach to investing much of the $75T in capital for Millennials and Gen Z.¹ These generations are 2X as likely to focus on altruistic investing and are shifting charitable contributions towards impactful, for-profit businesses since they believe they will drive broader, stickier change.²

In tandem with this shift, positively impactful businesses are valued at over $11T³ today with a CAGR of 19.5%.⁴ Perhaps more importantly, they're also performing stronger than traditional investments, particularly in times of market volatility.


¹Boss Magazine, The Great Wealth Transfer
²Fidelity, Millenial investors drive growth in impact investing
³AssetDash, Top Assets by Market Cap
⁴The Business Research Company, Investing Global Markets Report 2022

What Gets Us Excited.

Ensure people live longer, healthier lives.

  • Data-powered software for personalized care delivery
  • Novel modalities and platform therapeutics
  • AI-driven discovery and repurposing engines
  • CPG within deeply underserved TAMs built with novel formulations

On a planet that can stand the test of time.

  • Next generation Ag & Farming innovation, leveraging computer vision and AI
  • Sustainable materials, chemicals and industrials
  • Computing advancement
  • Aerospace & Defense

In a society where innovation reaches everyone.

  • Digital infrastructure for consumer / SMB enablement
  • Human advancement through vertically applied AI

The TVC Approach.

  • We invest early with conviction.
  • We personalize our support to help companies traverse the Valley of Death. (Read More)
  • We double down based on milestones, not time.
  • We are your most founder-aligned investor.

Our Team.

Nicholas Shekerdemian
Founding Partner
  • 2x Founder: Headstart (exit), Teaching by the Top
  • Thiel Fellow & YC, Summer 2017
  • 60+ Angel Investments
Nicole Seligman
Executive in Residence
  • Board Member, OpenAI and Intuitive Machines
  • Former Board Member, WPP and Paramount
  • President, Sony Corporation of America
  • Partner, Williams & Connolly LLP
Ines Ullmo
Associate
  • Venture Fellow, BlueYard Capital
  • PhD, Cancer Immunotherapy and Immunology, Imperial College London
Pete Ondishin
Chief Financial Officer
  • CFO, Kingstown Capital
  • Assistant Controller, Atlantic Investment Management
  • Assurance Senior Associate, PwC
Gina Shekerdemian
Founding Partner
  • Director, BlackRock
  • Forbes 30 Under 30
  • Yale University Advisory Board
Stephanie Sarelakos
Partner
  • Founding Member, Walmart eCommerce Incubator
  • Senior Manager, Jet.com
  • Financial Markets Advisory, BlackRock
Emily Aronin
Associate
  • Senior Investment Analyst, Valor Equity Partners
  • Commercial Development, Evozyne
Elliot Richmond
Senior Advisor
  • Partner, Moelis & Co
  • Director, Investment Banking, Merrill Lynch
  • 70+ angel investments
Cat Middleton
General Partner
  • Partner, Primary Ventures
  • Head of Due Diligence, PeopleTech Partners
  • VP People, Chartbeat
Chris Ghadban
Principal
  • Principal, Alix Ventures
  • Strategy & Innovation, AstraZeneca
  • MS, Bioengineering, Tufts University
Luke Lloyd-Davies
Chairman
  • Managing Director, Sir Elton John and David Furnish’s Global Private Office
  • COO, Rocket Entertainment Group
  • Advisor, MetroBank
Paula Sutter
Senior Advisor
  • CEO, TSG Fashion Group
  • President, Diane von Furstenberg
  • thredUP Board Member

Our Portfolio.

The TVC team has a track record of backing founders building purpose-driven businesses alongside world class investors. Some companies include:
Advanced Nuclear Energy to Empower Earth.
X-Energy Website
Leveraging synthetic biology to develop mRNA therapeutics for the world's most deadly cancers and diseases.
HelixNano Website
Data-driven, turnkey platform for tackling obesity.
FlyteHealth Website
Missions to the International Space Station today. The world’s first commercial space station tomorrow.
Axiom Space Website
unicorn
Unlocking the potential of macrocycle drug discovery through machine learning and massively parallel synthesis.
Unnatural Products Website
Better-for-you, better-for-the-planet gut health products.
Wonderbelly Website
Fast, accurate, and accessible AI-powered MRI imaging solutions.
Orbem Website
AI to understand the world around us.
Qloo Website

Venture Partners.

A global network of founders, operators, and investors who expand our experienced core team's ability to source and support TVC's growing portfolio of companies.

Kristin Thayer

  • Head of Partnerships, Watershed
  • Former Head of Travel Partnership, Uber; Former Partner, Andreessen Horowitz

Ariana Thacker

  • Founder, MoldCo
  • Founding Partner, Conscience VC
  • Investor, Rhapsody Venture Partners

Dr. James Gillespie

  • Chief Health Officer, Emoja Supply Chain Solutions
  • Co-Founder & President, Center for Healthcare Innovation
  • Senior Advisor, Stanford & Yale Schools of Medicine

Erica Dorfman

  • Head of Global Financial Products, Brex
  • Former: Head of Finance & Operations, Tally Technologies; Co-Head of Capital Markets, SoFi

Seanna Thompson

  • Senior Medical Director, Mount Sinai
  • Adjunct Professor of Health Administration, NYU
  • Senior Regional OBGYN Director, Mayo Clinic

Evan Segal

  • GP, 412 Ventures
  • Former CFO, US Department of Agriculture

Sanjiv Sanghavi

  • Co-Founder & CEO, Texture
  • Former Co-Founder, ClassPass (acq. Mindbody)

Brynn Putnam

  • Founder & Former CEO, MIRROR (acq. lululemon)

In Case You Missed It.

The latest and greatest from the TVC team and our portfolio.
Fierce Biotech
Argenx signs $1.5B pact to turn Unnatural Products' macrocyclic peptides to 'undruggable' targets
Argenx struck a deal worth $1.5B with Unnatural Products to develop macrocyclic peptide drugs for “undruggable” protein targets. UNP will handle early R&D, while argenx can take successful candidates to market. The deal includes milestones, royalties, and an equity investment.
Read More
Linkedin
Power100 Asset Managers In Venture Capital
Our firm is grateful to be honored alongside some of the best in the business. Thank you to Power100 Presented By Blueprint Capital Advisors LLC for the recognition.
Read More
Inc.com
Shizu Okusa Inc.com Founder Profile
Shizu Okusa has been recognized by Inc. as one of the 500 Female Founders to watch in 2025.
Read More

Contact Us.

Our team is easy to find online, but if you'd like to get in touch with us for press inquiries, membership applications, co-investment opportunities or something else entirely, please contact us below.

We look forward to hearing from you!